Mirae Asset Global Investments
ZNTL icon

Mirae Asset Global Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Mirae Asset Global Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,572
Closed -$9.64K – 1692
2024
Q3 		$9.64K Buy
2,572
+452
+21% +$1.64K ﹤0.01% 1500
2024
Q2 		$8.9K Sell
2,120
-29,467
-93% -$329K ﹤0.01% 1468
2024
Q1 		$522K Sell
31,587
-8,987
-22% -$124K ﹤0.01% 1878
2023
Q4 		$615K Buy
40,574
+5,917
+17% +$86.3K ﹤0.01% 1868
2023
Q3 		$695K Buy
34,657
+4,253
+14% +$108K ﹤0.01% 1724
2023
Q2 		$857K Buy
30,404
+569
+2% +$13.7K ﹤0.01% 1657
2023
Q1 		$513K Buy
29,835
+7,914
+36% +$160K ﹤0.01% 1906
2022
Q4 		$441K Buy
21,921
+4,515
+26% +$97.1K ﹤0.01% 1959
2022
Q3 		$377K Buy
17,406
+4,899
+39% +$134K ﹤0.01% 2040
2022
Q2 		$352K Buy
+12,507
New +$331K ﹤0.01% 1910

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Mirae Asset Global Investments's ZNTL Position: Q4 2024 in Review

Mirae Asset Global Investments sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 2,572 shares — an estimated $9.64K sold.

Mirae Asset Global Investments first reported a position in ZNTL in Q2 2022 and held it in 10 quarters. The position peaked at $857K in Q2 2023. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Mirae Asset Global Investments reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,572 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $9.64K.
  • Mirae Asset Global Investments first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Mirae Asset Global Investments's Zentalis Pharmaceuticals position peaked at $857K in Q2 2023.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.